4D Molecular Therapeutics
FDMT
94 hedge funds and large institutions have $522M invested in 4D Molecular Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 24 reducing their positions, and 15 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 24
5.05% more ownership
Funds ownership: 86.45% → 91.5% (+5%)
2% less funds holding
Funds holding: 96 → 94 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
16% less capital invested
Capital invested by funds: $622M → $522M (-$99.5M)
29% less call options, than puts
Call options by funds: $1.85M | Put options by funds: $2.6M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$13.6M |
| 3 |
CC
Casdin Capital
New York
|
+$8.56M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$8M |
| 5 |
Morgan Stanley
New York
|
+$5.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$13.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.37M |
| 3 |
Millennium Management
New York
|
-$6.38M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$5.86M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.36M |
FDMT Hedge Fund Activity: Q1 2023 in Review
94 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2023, worth a combined $522M — down 16% from $622M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of FDMT and 13 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 40 added.
The largest buyer was State Street, adding an estimated $15.7M. The largest seller was Commodore Capital, exiting entirely with an estimated $13.3M sold.
- 94 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2023, down from 96 in Q4 2022.
- Funds reported $522M of 4D Molecular Therapeutics stock for Q1 2023, down 16% quarter-over-quarter.
- 13 funds opened new 4D Molecular Therapeutics positions in Q1 2023 and 15 closed out, a net change of -2 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2023 was State Street, an estimated $15.7M added.
- The largest 4D Molecular Therapeutics seller in Q1 2023 was Commodore Capital, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2023.